SNStefanie Nass

Stefanie Nass

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefanie Nass has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Alex H.V. Remels

    School of Nutrition and Translational Research in Metabolism, Department of Pharmacology and Toxicology (A.H.V.R.), Maastricht University Medical Center+, the Netherlands

    1 shared publication
  • Casper G. Schalkwijk

    Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands

    1 shared publication
  • Emma B. N. J. Janssen

    Department of Obstetrics and Gynaecology, Maastricht University Medical Centre+ (MUMC+) , PO Box 5800, 6202 AZ Maastricht

    1 shared publication
  • Jean L. J. M. Scheijen

    CARIM School for Cardiovascular Disease, Maastricht University, 6229 ER Maastricht, The Netherlands

    1 shared publication
  • Marc E.A. Spaanderman

    School for Oncology and Developmental Biology, Department of Obstetrics and Gynaecology (S.A.-N., E.J., M.E.A.S.), Maastricht University Medical Center+, the Netherlands

    1 shared publication
  • Paul M.H. Schiffers

    School for Cardiovascular Diseases, Department of Pharmacology and Toxicology (P.M.H.S.), Maastricht University Medical Center+, the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Placental Methylglyoxal in Preeclampsia: Vascular and Biomarker Implications

    by Philippe Vangrieken, Salwan Al-Nasiry, Alex H.V. Remels, Paul M.H. Schiffers, Emma Janssen, Stefanie Nass, Jean L.J.M. Scheijen, Marc E.A. Spaanderman, Casper G. Schalkwijk

    BACKGROUND: Preeclampsia is a multifaceted syndrome that includes maternal vascular dysfunction. We hypothesize that increased placental glycolysis and hypoxia in preeclampsia lead to increased levels of methylglyoxal (MGO), consequently causing vascular dysfunction. METHODS: Plasma samples and placentas were collected from uncomplicated and preeclampsia pregnancies. Uncomplicated placentas and trophoblast cells (BeWo) were exposed to hypoxia. The reactive dicarbonyl MGO and advanced glycation end products (N ε -(carboxymethyl)lysine [CML], N ε -(carboxyethyl)lysine [CEL], and MGO-derived hydroimidazolone [MG-H]) were quantified using liquid chromatography-tandem mass spectrometry. The activity of GLO1 (glyoxalase-1), that is, the enzyme detoxifying MGO, was measured. The impact of MGO on vascular function was evaluated using wire/pressure myography. The therapeutic potential of the MGO-quencher quercetin and mitochondrial-specific antioxidant mitoquinone mesylate (MitoQ) was explored. RESULTS: MGO, CML, CEL, and MG-H2 levels were elevated in preeclampsia-placentas (+36%, +36%, +25%, and +22%, respectively). Reduced GLO1 activity was observed in preeclampsia-placentas (−12%) and hypoxia-exposed placentas (−16%). Hypoxia-induced MGO accumulation in placentas was mitigated by the MGO-quencher quercetin. Trophoblast cells were identified as the primary source of MGO. Reduced GLO1 activity was also observed in hypoxia-exposed BeWo cells (−26%). Maternal plasma concentrations of CML and the MGO-derived MG-H1 increased as early as 12 weeks of gestation (+16% and +17%, respectively). MGO impaired endothelial barrier function, an effect mitigated by MitoQ, and heightened vascular responsiveness to thromboxane A2. CONCLUSIONS: This study reveals the accumulation of placental MGO in preeclampsia and upon exposure to hypoxia, demonstrates how MGO can contribute to vascular impairment, and highlights plasma CML and MG-H1 levels as promising early biomarkers for preeclampsia.